Abstract
Aminopeptidase N (CD13) as the malignant cell surface marker is overexpressed on many tumor cells including lung cancer and the neovascular cell membranes. A tripeptide structure, Asn-Gly-Arg (NGR), can specifically bind to CD13. In this study, we successfully labeled various NGR peptides derivatives with FITC or 177Lu at high efficiency. The 177Lu labeling of the NGR peptides was stable in vitro. The cellular uptake of the 177Lu-labeled cyclic NGR peptides was different by varying the structure of peptides.
Similar content being viewed by others
References
Risau W, Flamme I (1995) Vasculogenesis. Annu Rev Cell Dev Biol 11:73–91
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27–31
Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 2(5):529–533
Guzman-Rojas L, Rangel R, Salameh A, Edwards JK, Dondossola E, Kim YG, Saghatelian A, Giordano RJ, Kolonin MG, Staquicini FI, Koivunen E, Sidman RL, Arap W, Pasqualini R (2012) Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci USA 109(5):1637–1642
Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischaluck J, Lenz G, Wardelmann E, Mesters RM, Schwoppe C, Berdel WE, Hartmann W, Schliemann C (2018) Aminopeptidase N (CD13): expression, prognostic Impact, and use as therapeutic target for tissue factor induced tumor vascular infarction in soft tissue sarcoma. Transl Oncol 11(6):1271–1282
Wickstrom M, Larsson R, Nygren P, Gullbo J (2011) Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 102(3):501–508
Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M (2003) Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 9(4):1503–1508
Pang L, Zhang N, Xia Y, Wang D, Wang G, Meng X (2016) Serum APN/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer. Oncotarget 7(47):77854–77864
Bieker R, Kessler T, Schwoppe C, Padro T, Persigehl T, Bremer C, Dreischaluck J, Kolkmeyer A, Heindel W, Mesters RM, Berdel WE (2009) Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 113(20):5019–5027
Meng Y, Zhang Z, Liu K, Ye L, Liang Y, Gu W (2018) Aminopeptidase N (CD13) targeted MR and NIRF dual-modal imaging of ovarian tumor xenograft. Mater Sci Eng C Mater Biol Appl 93:968–974
Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349):377–380
Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Gorlich D, Marra A, Hillejan L, Muller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwoppe C, Hartmann W (2017) Potential therapeutic impact of CD13 expression in non-small cell lung cancer. PLoS ONE 12(6):e0177146
Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Gorlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwoppe C, Hartmann W (2017) CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. Lung Cancer 113:121–127
Brand C, Frohlich M, Ring J, Schliemann C, Kessler T, Mantke V, Konig S, Lucke M, Mesters RM, Berdel WE, Schwoppe C (2015) Tumor growth inhibition via occlusion of tumor vasculature induced by N-terminally PEGylated retargeted tissue factor tTF-NGR. Mol Pharm 12(10):3749–3758
Colombo G, Curnis F, De Mori GM, Gasparri A, Longoni C, Sacchi A, Longhi R, Corti A (2002) Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277(49):47891–47897
Persigehl T, Ring J, Bremer C, Heindel W, Holtmeier R, Stypmann J, Claesener M, Hermann S, Schafers M, Zerbst C, Schliemann C, Mesters RM, Berdel WE, Schwoppe C (2014) Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging. Angiogenesis 17(1):235–246
Vats K, Satpati D, Sharma R, Kumar C, Sarma HD, Dash A (2017) (99 m) Tc-labeled NGR-chlorambucil conjugate, (99 m) Tc-HYNIC-CLB-c(NGR) for targeted chemotherapy and molecular imaging. J Labelled Comp Radiopharm 60(9):431–438
Vats K, Satpati D, Sharma R, Sarma HD, Banerjee S (2017) Synthesis and comparative in vivo evaluation of (99 m) Tc(CO)3 -labeled PEGylated and non-PEGylated cRGDfK peptide monomers. Chem Biol Drug Des 89(3):371–378
Shao Y, Liang W, Kang F, Yang W, Ma X, Li G, Zong S, Chen K, Wang J (2014) 68 Ga-labeled cyclic NGR peptide for microPET imaging of CD13 receptor expression. Molecules 19(8):11600–11612
Li G, Wang X, Zong S, Wang J, Conti PS, Chen K (2014) MicroPET imaging of CD13 expression using a (64)Cu-labeled dimeric NGR peptide based on sarcophagine cage. Mol Pharm 11(11):3938–3946
Satpati D, Sharma R, Kumar C, Sarma HD, Dash A (2017) (68)Ga-Chelation and comparative evaluation of N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) conjugated NGR and RGD peptides as tumor targeted molecular imaging probes. Medchemcomm 8(3):673–679
Satpati D, Sharma R, Sarma HD, Dash A (2018) Comparative evaluation of (68) Ga-labeled NODAGA, DOTAGA, and HBED-CC-conjugated cNGR peptide chelates as tumor-targeted molecular imaging probes. Chem Biol Drug Des 91(3):781–788
Chen K, Ma W, Li G, Wang J, Yang W, Yap LP, Hughes LD, Park R, Conti PS (2013) Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression. Mol Pharm 10(1):417–427
Zhuo L, Yang X, Liao W, Wang J, Wang H, Lv M, Wang G, Song H, Feng Y, Chen Y, Wei H, Yang Y, Zhao P (2019) Comparative cell uptake study of FITC-/177Lu-labeled RM26 monomer, dimer and trimer on PC-3: improving binding affinity of gastrin releasing peptide receptor (GRPR) antagonist via bivalency/trivalency. J Radioanal Nucl Chem 319(3):881–889
Vats K, Satpati AK, Sharma R, Sarma HD, Satpati D, Dash A (2018) (177)Lu-labeled cyclic Asn-Gly-Arg peptide tagged carbon nanospheres as tumor targeting radio-nanoprobes. J Pharm Biomed Anal 152:173–178
Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, Di Matteo P, Traversari C, Bachi A, Ponzoni M, Rizzardi GP, Corti A (2010) Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. J Biol Chem 285(12):9114–9123
Huang Y, Wang X, Huang W, Cheng Q, Zheng S, Guo S, Cao H, Liang XJ, Du Q, Liang Z (2015) Systemic administration of siRNA via cRGD-containing peptide. Sci Rep 5:12458
Achbergerova E, Smejkalova D, Huerta-Angeles G, Soucek K, Hermannova M, Vagnerova H, Vicha R, Velebny V (2018) In vivo monitoring of tumor distribution of hyaluronan polymeric micelles labeled or loaded with near-infrared fluorescence dye. Carbohydr Polym 198:339–347
Acknowledgements
This work was funded from the National Key R&D Program of China (2017YFC1200403), the National Natural Science Foundation of China (Grant Nos. 21976167 and 21906155), and Nuclear Energy Development Project of State Administration of Science, Technology and Industry for National Defense (20181524-1).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ding, Z., Fu, H., Li, X. et al. Preparation and cellular-interaction investigation of 177Lu/FITC labeled NGR peptides. J Radioanal Nucl Chem 325, 67–74 (2020). https://doi.org/10.1007/s10967-020-07223-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-020-07223-4